B. Schlemmer, Antibiotic sparing campaigns and the French Antibiotic Plan], Rev Prat, vol.23262, pp.972-977, 2012.

G. Cornaglia, W. Hryniewicz, V. Jarlier, G. Kahlmeter, H. Mittermayer et al., European recommendations for antimicrobial resistance surveillance, Clinical Microbiology and Infection, vol.10, issue.5, pp.349-83, 2004.
DOI : 10.1111/j.1469-0691.2004.00924.x

C. Arpin, C. Quentin, F. Grobost, E. Cambau, J. Robert et al., Nationwide survey of extended-spectrum ??-lactamase-producing Enterobacteriaceae in the French community setting, Journal of Antimicrobial Chemotherapy, vol.63, issue.6, pp.1205-1219, 2009.
DOI : 10.1093/jac/dkp108
URL : https://hal.archives-ouvertes.fr/hal-00426312

F. Bert, 10-Fold increase (2006-11) in the rate of healthy subjects with extended- 244 spectrum ?-lactamase-producing Escherichia coli faecal carriage in a Parisian check-up 245 centre, J Antimicrob Chemother, vol.68, pp.562-570, 2013.

E. Esteve-palau, G. Solande, F. Sánchez, L. Sorlí, M. Montero et al., Clinical 248 and economic impact of urinary tract Infections caused by ESBL-producing 249

S. A. Edimark, Epidémiologie de la Résistance Bactérienne aux Antibiotiques 253 (ONERBA) Recommandations méthodologiques pour la surveillance de la résistance 254 aux antibiotiques dans les laboratoires de microbiologie (www.onerba.org), pp.682-90, 2000.

R. Colodner, W. Rock, B. Chazan, N. Keller, N. Guy et al., Risk Factors for the Development of Extended-Spectrum Beta-Lactamase-Producing Bacteria in Nonhospitalized Patients, European Journal of Clinical Microbiology & Infectious Diseases, vol.23, issue.3, pp.163-170, 2004.
DOI : 10.1007/s10096-003-1084-2

O. Azap, H. Arslan, K. Serefhano?lu, S. Colako?lu, H. Erdo?an et al., 305 Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic 306

. Société-de-pathologie-infectieuse-de-langue-française, Diagnostic et antibiothérapie 310 des infections urinaires bactériennes communautaires de l'adulte, pp.2014-312, 2015.

A. Søraas, A. Sundsfjord, S. Jørgensen, K. Liestøl, and P. Jenum, High rate of per oral 319 mecillinam treatment failure in community-acquired urinary tract infections caused by 320 ESBL-producing Escherichia coli, PLoS One, vol.9, 2014.